TITLE

Azithromycin Three Times a Week Could Prevent COPD Exacerbations

PUB. DATE
November 2012
SOURCE
AARC Times;Nov2012, Vol. 36 Issue 11, p71
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports a study conducted by the Virginia Commonwealth University suggesting routine intake of the antibiotic azithromycin, three times a week would prevent acute exacerbations of chronic obstructive pulmonary disease (COPD).
ACCESSION #
83167272

 

Related Articles

  • Azithromycin reduces risk of COPD exacerbations.  // Pulse;9/7/2011, Vol. 71 Issue 28, p14 

    The article reports on the result of a new study conducted by U.S. researchers which shows that patients with chronic obstructive pulmonary disease (COPD), who intake azithromycin have lessened the risk of exacerbations.

  • I have chronic obstructive pulmonary disease (COPD) and my doctor is recommending an antibiotic drug long term. Why is this needed?  // Mayo Clinic Health Letter;Dec2015, Vol. 33 Issue 12, p8 

    The article provides an answer to the question of why the doctor recommended an antibiotic drug long term for his chronic obstructive pulmonary disease (COPD).

  • The Effect of Azithromycin in Adults with Stable Neutrophilic COPD: A Double Blind Randomised, Placebo Controlled Trial. Simpson, Jodie L.; Powell, Heather; Baines, Katherine J.; Milne, David; Coxson, Harvey O.; Hansbro, Philip M.; Gibson, Peter G. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive airway disease characterised by neutrophilic airway inflammation or bronchitis. Neutrophilic bronchitis is associated with both bacterial colonisation and lung function decline and is common in exacerbations of COPD....

  • A double-blind, randomised, placebocontrolled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. Shafuddin, Eskandarain; Mills, Graham D.; Holmes, Mark D.; Poole, Phillippa J.; Mullins, Peter R.; Black, Peter N. // Journal of Negative Results in Biomedicine;10/9/2015, Vol. 14 Issue 1, p1 

    Background: Azithromycin prophylaxis has been shown to reduce COPD exacerbations but there is poor evidence for other antibiotics. We compared exacerbation rates in COPD patients with a history of frequent exacerbations (at least three moderate or severe COPD exacerbations in the past two years)...

  • Long-Term Azithromycin for Prophylaxis of COPD Exacerbations. Kuritzky, Louis // Primary Care Reports;Nov2011 Clinical Briefs in Primary, p22 

    The article focuses on a study of the effect of long-term azithromycin prophylaxis on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) conducted by R. K. Albert and colleagues and published in a 2011 issue of "The New England Journal of Medicine."

  • Azithromycin does not look cardiotoxic in a general population.  // BMJ: British Medical Journal;5/11/2013, Vol. 346 Issue 7907, p9 

    The article reports a study which found that azithromycin use was not associated with an increased risk of death from cardiovascular causes in a general population of young and middle-aged adults.

  • Azithromycin reduced exacerbations in COPd patients.  // Australian Journal of Pharmacy;May2012, Vol. 93 Issue 1104, p94 

    The article reports on a study conducted to examine effects of azithromycin on exacerbations in patients with chronic obstructive pulmonary disease (COPD). A randomized controlled follow-up study was carried out where individuals were administered aspirin for one year. The results concluded that...

  • TRACHOMA CONTROL. Solomon, Anthony W.; Baltussen, R.; Smith, A.; Chisholm, D. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/14/2012, Vol. 344 Issue 7852, p30 

    A letter to the editor is presented in response to the article "What are the Priorities for Prevention and Control of Non-Communicable Diseases and Injuries in Sub-Saharan Africa and South East Asia," by D. Chisholm and colleagues in the March 2, 2012 issue.

  • Azithromycin: Double-edged Sword in Treatment of Non-CF Bronchiectasis.  // AARC Times;Jul2013, Vol. 37 Issue 7, p139 

    The article discusses a study published in the March 27, 2013 edition of "The Journal of the American Medical Association" about the effectiveness of low-dose macrolide therapy in reducing exacerbation frequency in patients with non-cystic fibrosis bronchiectasis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics